Acalabrutinib‐related second primary malignancies and nonmelanoma skin cancers in patients with chronic lymphocytic leukaemia (CLL): A systematic review and meta‐analysis of randomised controlled trials (RCTs)

Acalabrutinib is a second generation Bruton's tyrosine kinase inhibitor and was recently approved in the treatment of chronic lymphocytic leukaemia. We undertook a systematic review and meta‐analysis of randomised controlled trials to determine the risks of acalabrutinib‐related second primary...

Descripción completa

Detalles Bibliográficos
Autores principales: Htut, Thura W., Han, Myat M., Thein, Kyaw Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175848/
https://www.ncbi.nlm.nih.gov/pubmed/35846092
http://dx.doi.org/10.1002/jha2.146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175848/
https://www.ncbi.nlm.nih.gov/pubmed/35846092
http://dx.doi.org/10.1002/jha2.146

Ejemplares similares